Cargando…

Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety

Lipid nanoparticle (LNP) formulated messenger RNA-based (LNP-mRNA) vaccines came into the spotlight as the first vaccines against SARS-CoV-2 virus to be applied worldwide. Long-known benefits of mRNA-based technologies consisting of relatively simple and fast engineering of mRNA encoding for antigen...

Descripción completa

Detalles Bibliográficos
Autor principal:	Vlatkovic, Irena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151051/ https://www.ncbi.nlm.nih.gov/pubmed/34068715 http://dx.doi.org/10.3390/biomedicines9050530

Ejemplares similares

Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects
por: Kiaie, Seyed Hossein, et al.
Publicado: (2022)

ASL mRNA-LNP Therapeutic for the Treatment of Argininosuccinic Aciduria Enables Survival Benefit in a Mouse Model
por: Daly, Owen, et al.
Publicado: (2023)

The effects of PEGylation on LNP based mRNA delivery to the eye
por: Ryals, Renee C., et al.
Publicado: (2020)

Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
por: Peng, Lei, et al.
Publicado: (2022)

Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability
por: Zhang, Lizhou, et al.
Publicado: (2023)

Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines
por: Somiya, Masaharu, et al.
Publicado: (2021)

COVID-19 mRNA vaccines: Platforms and current developments
por: Szabó, Gábor Tamás, et al.
Publicado: (2022)

mRNA-LNP vaccination-based immunotherapy augments CD8(+) T cell responses against HPV-positive oropharyngeal cancer
por: Qiu, Ke, et al.
Publicado: (2023)

Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
por: Fedorowski, Jaroslaw J.
Publicado: (2021)

Determination of significant immunological timescales from mRNA-LNP-based vaccines in humans
por: Moyles, Iain R., et al.
Publicado: (2023)

Impact of Ribosome Activity on SARS-CoV-2 LNP – Based mRNA Vaccines
por: Tsiambas, Evangelos, et al.
Publicado: (2021)

Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells
por: Maugeri, Marco, et al.
Publicado: (2019)

Ionizable Lipids with Triazole Moiety from Click Reaction for LNP-Based mRNA Delivery
por: Wang, Yixiang, et al.
Publicado: (2023)

The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2
por: Granados-Riveron, Javier T., et al.
Publicado: (2021)

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
por: Ndeupen, Sonia, et al.
Publicado: (2021)

Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice
por: Zhang, Mengling, et al.
Publicado: (2020)

Single-cell suspension preparation from murine organs following in vivo mRNA-LNP exposure
por: Ndeupen, Sonia, et al.
Publicado: (2022)

Intranasal mRNA-LNP vaccination protects hamsters from SARS-CoV-2 infection
por: Baldeon Vaca, Gabriela, et al.
Publicado: (2023)

Development and Characterization of an In Vitro Cell-Based Assay to Predict Potency of mRNA–LNP-Based Vaccines
por: Patel, Nisarg, et al.
Publicado: (2023)

An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates
por: Ripoll, Manon, et al.
Publicado: (2022)

Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice
por: Kenjo, Eriya, et al.
Publicado: (2021)

Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
por: Liu, Cong, et al.
Publicado: (2022)

Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques
por: Valentin, Antonio, et al.
Publicado: (2022)

Validation of an HPLC-CAD Method for Determination of Lipid Content in LNP-Encapsulated COVID-19 mRNA Vaccines
por: Yu, Xiaojuan, et al.
Publicado: (2023)

Immunization with a novel mRNA vaccine, TGGT1_216200 mRNA-LNP, prolongs survival time in BALB/c mice against acute toxoplasmosis
por: Zhang, Yizhuo, et al.
Publicado: (2023)

Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022)

Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion
por: Qin, Zhen, et al.
Publicado: (2022)

Pre-exposure to mRNA-LNP inhibits adaptive immune responses and alters innate immune fitness in an inheritable fashion
por: Qin, Zhen, et al.
Publicado: (2022)

mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells
por: Bevers, Sanne, et al.
Publicado: (2022)

An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization
por: Hsu, Fu-Fei, et al.
Publicado: (2022)

mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum
por: Hayashi, Clifford T. H., et al.
Publicado: (2022)

Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage
por: Radloff, Katrin, et al.
Publicado: (2023)

mRNA therapeutics in cancer immunotherapy
por: Beck, Jan D., et al.
Publicado: (2021)

mRNA vaccine for cancer immunotherapy
por: Miao, Lei, et al.
Publicado: (2021)

mRNA delivery in cancer immunotherapy
por: Zhong, Yichen, et al.
Publicado: (2023)

Development of an mRNA-LNP Vaccine against SARS-CoV-2: Evaluation of Immune Response in Mouse and Rhesus Macaque
por: Naderi Sohi, Alireza, et al.
Publicado: (2021)

Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin
por: Huysmans, Hanne, et al.
Publicado: (2019)

A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium
por: Kon, Edo, et al.
Publicado: (2023)

A multiple-target mRNA-LNP vaccine induces protective immunity against experimental multi-serotype DENV in mice
por: He, Lihong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o13fnpntfc4omdbd5ejpgoe5ua